Do you want to invest in Veriphi?

Veriphi is an exciting Medtech company that aims to globally transform intravenous medication delivery, the most common, high-risk patient intervention in hospitals. One million hospital patients are harmed every year by preventable medication error in the United States alone. 

Over the last 15 years, we have developed a groundbreaking spectral analyser that uses lasers, artificial intelligence and cloud computing to verify drug identity and concentration to ensure that intravenous drug administration is safe and accurate. The analyser, and the know-how gained, is a technological breakthrough recognised by 22 granted global patents, including eight granted US patents.

In 2025, we signed our first commercial supply agreement with St Vincent’s Hospital, Melbourne.

We are currently raising NZ$5 million to help drive sales in the Australian market as well as begin to explore opportunities in the US.

Register your interest below, and we will add you to our investor newsletter.